Trial Profile
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Neuromyelitis optica
- Focus Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 03 May 2014 New trial record